Keywords: lunesta, misses, ph, ii, efficacy, endpoints, drugmaker

Lunesta misses Ph II efficacy endpoints

Article | 16 March 2009

Print This

US drugmaker Sepracor's Lunesta (eszopiclone) failed to demonstrate efficacy in a mid-stage trial, assessing the drug for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in